Bridging across the ampulla of Vater with covered self-expanding metallic stents: is it contraindicated when treating malignant gastroduodenal obstruction?
To determine if concern for biliary obstruction constitutes a contraindication to the placement of a covered self-expandable metallic stent (SEMS) bridging the ampulla of Vater (AOV). Retrospective review of fluoroscopic images of stent placement was performed in 62 patients (43 men; mean age, 62 years) with malignant gastroduodenal obstruction treated with a partially covered SEMS. Bare (n = 35) and covered (n = 27) stent portions were placed to bridge the AOV. Preprocedural and postprocedural bilirubin and alkaline phosphatase (ALP) levels were reviewed. The incidence of external biliary drainage tube insertion within 1 month was compared between groups. In 27 patients with postprocedural computed tomography studies, causes of bile duct dilation were evaluated. Compared to preprocedural data, postprocedural bilirubin and ALP levels were elevated significantly in both groups (bilirubin, mg/dL, 1.8 +/- 2.3 vs 2.8 +/- 3.7, P = .02 for bare, 1.6 +/- 1.7 vs 3.6 +/- 4.4, P = .02 for covered; ALP, IU/L, 193.2 +/- 174.8 vs 292.9 +/- 293.7, P = .01 for bare, 214.7 +/- 213.3 vs 357.6 +/- 234.4, P < .01 for covered group). Changes in laboratory measurements were not significantly different between groups (bilirubin, 1.1 mg/dL +/- 2.2 and 2.2 mg/dL +/- 4.0 in bare and covered groups, respectively [P = .19]; ALP, 128.9 IU/L +/- 207.0 and 156.3 IU/L +/- 136.1, respectively [P = .56]). The incidence of external biliary drainage tube insertion was not significantly different between groups (17.1% and 25.9% in bare and covered stent groups, P = .53). The stent was the cause of bile duct dilation in only one patient. It is suggested that it is not contraindicated to place a covered SEMS to bridge the AOV.